Skip to content
Subscriber Only

Johnson & Johnson’s Fast-Acting Depression Drug Is Approved

  • Drug is first major advance in depression drugs since Prozac
  • Companies like Sage, Allergan also studying fast-acting drugs
Updated on

Severely depressed patients will have a new, fast-acting treatment option after the U.S. approved a breakthrough drug that has the potential to upend how the condition is treated.

The Food and Drug Administration on Tuesday greenlighted Johnson & Johnson’s nasal spray Spravato, a close chemical cousin of the anesthetic ketamine that works quickly to alleviate symptoms of depression.